Timdarpacept

替达派西普

Report date: 2026/04/16 20:00:17

Base Information

Drug NameTimdarpacept
Drug Alias NameSIRPαFc(ImmuneOnco)IMM01IMM 01IMC-001
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCluster of differentiation 47 inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsMacrophages stimulants +[5] 
TargetsCluster of differentiation 47
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesAtherosclerosis +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesYiming Kell Biomedical Technology (Shanghai) Co LtdImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursMyelodysplastic SyndromesAtherosclerosis +[8] 
Inactive IndicationsCardiovascular DiseasesHematologic NeoplasmsMultiple Myeloma +[6] 

Other Information

ATC CodeN/A
Related LinksDrugBank